ActiveOps FY26 slides: ARR surges 46% as NRR hits record 119%

ActiveOps (AIM:AOM) reported FY26 annual recurring revenue up 46% to £41.5m and net revenue retention at a record 119% (vs 108–110% historical), alongside adjusted EBITDA up 72% to £4.3m and margin expansion to 10% from 8%. Revenue rose to £45.0m (from £30.5m in FY25) with 23% organic SaaS growth and 84% gross margins maintained. The Enlighten acquisition is progressing ahead of schedule, with £3.0m in annualized cost savings already achieved, and management reiterated an FY27 outlook aimed at growing toward £100m ARR with 25% EBITDA margins.

Analysis

The signal is not the headline growth rate; it is the quality of that growth. When expansion is driven by installed-base upsell and higher seat density, the market can eventually underwrite a higher multiple because ARR becomes less dependent on expensive new-logo acquisition. That said, in a subscale enterprise software name, the valuation re-rate usually happens only after 2-3 clean quarters of conversion, not on one strong print.

The main near-term risk is that commercial headcount expansion outruns bookings productivity. If the added sales capacity is real, it should show up over the next 1-2 reporting periods in new-logo wins and faster ARR adds; if not, margin leverage will look temporary. The other key falsifier is retention normalization: a drift back toward the prior 108%-110% zone would imply the current expansion is more price/upgrade driven than durable platform penetration.

Contrarian view: the market may be overassigning an AI-growth multiple to what is still fundamentally a workflow optimization tool. The bigger second-order benefit is budget defensibility in a tighter enterprise spend environment, because the product sells savings, not experimentation. But that also means larger platforms like ServiceNow, NICE, or broader HCM/automation suites could pressure pricing if they bundle comparable analytics into existing contracts over 6-18 months.

Key Decisions for Investors

• AOM.L: Buy on post-results weakness only; preferred entry is a 5-8% pullback from current levels, with a 6-12 month hold. Thesis is that sustained NRR >115% can justify a higher small-cap SaaS multiple, but upside is capped if the market already priced the print.
• AOM.L: Set a hard watchlist trigger for thesis damage at NRR <112% or ARR growth decelerating below ~20% organic over the next two reporting cycles; that would argue the expansion engine is less durable than management suggests.
• Relative value: long AOM.L vs. a basket of larger-cap workflow/automation software (e.g., NOW/NICE/PEGA) on a 6-18 month horizon if you want to express belief in specialized vertical software monetization without taking broad software beta.
• No trade in TGT from this item; the read-through is too remote. Treat this as a small-cap UK software-specific setup rather than a general tech beta event.